Rohwedder K - Search Results

1

Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population.

Tangri N, Ferguson T, Leon SJ, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Farjat AE, Farag YMK, Schloemer P, Lawatscheck R, Rohwedder K, Bakris GL. Tangri N, et al. Among authors: rohwedder k. Clin Kidney J. 2024 Mar 6;17(4):sfae052. doi: 10.1093/ckj/sfae052. eCollection 2024 Apr. Clin Kidney J. 2024. PMID: 38650758 Free PMC article.

2

Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance.

Ebert T, Anker SD, Ruilope LM, Fioretto P, Fonseca V, Umpierrez GE, Birkenfeld AL, Lawatscheck R, Scott C, Rohwedder K, Rossing P; FIDELIO-DKD and FIGARO-DKD Investigators. Ebert T, et al. Among authors: rohwedder k. Diabetes Care. 2024 Mar 1;47(3):362-370. doi: 10.2337/dc23-1420. Diabetes Care. 2024. PMID: 38151465 Free PMC article. Clinical Trial.

3

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.

Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Among authors: rohwedder k. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.

4

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes.

Aberle J, Menzen M, Schmid SM, Terkamp C, Jaeckel E, Rohwedder K, Scheerer MF, Xu J, Tang W, Birkenfeld AL. Aberle J, et al. Among authors: rohwedder k. Sci Rep. 2020 Dec 28;10(1):22396. doi: 10.1038/s41598-020-78734-z. Sci Rep. 2020. PMID: 33372185 Free PMC article. Clinical Trial.

5

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.

Müller-Wieland D, Kellerer M, Cypryk K, Skripova D, Rohwedder K, Johnsson E, Garcia-Sanchez R, Kurlyandskaya R, Sjöström CD, Jacob S, Seufert J, Dronamraju N, Csomós K. Müller-Wieland D, et al. Among authors: rohwedder k. Diabetes Obes Metab. 2018 Nov;20(11):2598-2607. doi: 10.1111/dom.13437. Epub 2018 Jul 16. Diabetes Obes Metab. 2018. PMID: 29947099 Free PMC article. Clinical Trial.

6

Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016).

Rathmann W, Scheerer M, Rohwedder K, Busch S, Kostev K. Rathmann W, et al. Among authors: rohwedder k. Postgrad Med. 2018 Mar;130(2):244-250. doi: 10.1080/00325481.2018.1421842. Epub 2018 Jan 1. Postgrad Med. 2018. PMID: 29291638

7

Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52 weeks.

Grandy S, Sternhufvud C, Ryden A, Sugg J, Rohwedder K. Grandy S, et al. Among authors: rohwedder k. Diabetes Obes Metab. 2016 Mar;18(3):306-9. doi: 10.1111/dom.12604. Epub 2016 Jan 5. Diabetes Obes Metab. 2016. PMID: 26537439 Clinical Trial.

8

Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.

Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E; Study 05 Group. Matthaei S, et al. Among authors: rohwedder k. Diabetes Obes Metab. 2015 Nov;17(11):1075-84. doi: 10.1111/dom.12543. Epub 2015 Sep 4. Diabetes Obes Metab. 2015. PMID: 26212528 Clinical Trial.

9

Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.

Del Prato S, Nauck M, Durán-Garcia S, Maffei L, Rohwedder K, Theuerkauf A, Parikh S. Del Prato S, et al. Among authors: rohwedder k. Diabetes Obes Metab. 2015 Jun;17(6):581-590. doi: 10.1111/dom.12459. Epub 2015 Apr 6. Diabetes Obes Metab. 2015. PMID: 25735400 Clinical Trial.

10

Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.

Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S; Study 05 Group. Matthaei S, et al. Among authors: rohwedder k. Diabetes Care. 2015 Mar;38(3):365-72. doi: 10.2337/dc14-0666. Epub 2015 Jan 15. Diabetes Care. 2015. PMID: 25592197 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page